Novartis announced that its investigational drug Vanrafia has successfully demonstrated the ability to slow kidney function decline in adults living with IgA nephropathy (IgAN), a chronic and ...
Everyday Health on MSN
Novel targeted therapies for IgAN: What you need to know
Explore novel therapies for IgA nephropathy that target inflammation and antibody production. Learn how these advancements ...
Novartis today announced final results from the Phase III ALIGN study supporting a slowing decline in kidney function in adults with IgA nephropathy (IgAN) who were treated with Vanrafia (atrasentan).
New KDIGO updates push earlier IgA nephropathy treatment, targeting immune pathways and nephron protection to cut proteinuria and slow eGFR decline. In this episode, Integrating Risk Stratification ...
Long-term data from the phase 3 ALIGN trial reinforce the safety and efficacy of atrasentan for patients with immunoglobulin A nephropathy.
IgA nephropathy, also known as Berger’s disease, is a progressive, autoimmune, chronic kidney disease that predominantly affects adults between the ages of 20 and 40. It is characterized by the ...
Add Yahoo as a preferred source to see more of our stories on Google. May 11—(StatePoint) IgA nephropathy is a progressive, autoimmune, chronic disease that predominantly affects adults between the ...
Dr Suneel Udani vividly recalls, as a first-year fellow, caring for a patient with IgA nephropathy whose condition deteriorated despite their best efforts, due to the limited treatment options ...
IgA nephropathy is a disease that can cause scarring in the kidneys. The kidney scarring from IgA nephropathy cannot be reversed once it occurs. While IgA nephropathy can't be reversed, treatment can ...
IgAN and IBD are both autoimmune conditions, and research indicates a strong association between them, with people who have IgAN having a higher risk of developing IBD. IBD can negatively impact ...
Robert Burakoff, MD, MPH, is a board-certified gastroenterologist who serves as vice chair of Ambulatory Services at Lower Manhattan Hospital and professor of medicine at the Weill Cornell Medical ...
In ALIGN study, Vanrafia (atrasentan) showed positive difference in eGFR change from baseline vs. placebo at Week 136, 4 weeks after study treatment ended1Results favored Vanrafia across multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results